“Therapeutic resistance is a main obstacle to achieving effective and durable cancer treatments,” said corresponding author Dr. Weei-Chin Lin, professor of medicine—hematology and oncology—and molecular and cellular biology at Baylor. “While some therapies are effective at the beginning, many patients eventually relapse because cancer cells can activate compensatory and convergent biological pathways that allow them to overcome the toxic effects of therapy, promoting survival.”